Could estrogen exposure explain why some pituitary tumors grow larger?

NCT ID NCT07268183

Recruiting now Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether higher lifetime exposure to estrogen—from sources like birth control, pregnancy, or hormone therapy—is linked to the development of larger prolactin-secreting pituitary tumors (macroprolactinomas) compared to smaller ones (microprolactinomas). Researchers will compare estrogen exposure histories in 180 women diagnosed with either type of tumor. The goal is to identify potential risk factors that might explain why some tumors grow larger.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If this study finds a link, it could help doctors understand why some women develop larger prolactinomas and possibly guide future prevention or monitoring strategies.
What could go wrong: This is an observational study using questionnaires, so it cannot prove cause and effect. Results may be limited by recall bias or other unmeasured factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MACROPROLACTINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pituitary Neoplasms prolactin-producing pituitary gland adenoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MACROPROLACTINOMA PROLACTINOMA

Contacts and locations

Locations

Hopital Louis Pradel
RECRUITING

Bron, Rhone, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.